Welcome to our dedicated page for Anaptysbio news (Ticker: ANAB), a resource for investors and traders seeking the latest updates and insights on Anaptysbio stock.
AnaptysBio Inc (ANAB) is a clinical-stage biotechnology company advancing antibody therapies for autoimmune and inflammatory diseases through its proprietary discovery platforms. This page aggregates official news releases, clinical trial milestones, and strategic partnership announcements directly from the company and verified sources.
Investors and researchers will find timely updates on pipeline developments, regulatory progress, and financial disclosures, including updates on checkpoint agonists and cytokine antagonists in clinical testing. The curated collection serves as a centralized hub for tracking the company’s progress in immunology therapeutics and antibody discovery.
Content spans phase trial results, licensing agreements, and technology innovations related to the shm-xel platform. Bookmark this page for efficient access to AnaptysBio’s latest advancements in developing treatments for conditions like atopic dermatitis and ulcerative colitis.
AnaptysBio (ANAB) reported Q2 2022 results, highlighting an operating cash position of $572.1 million, with anticipated net cash burn estimated at $90-$100 million for 2022.
Collaboration revenue fell significantly to $1.2 million compared to $30 million a year prior. Research and development expenses decreased to $20.8 million, while general and administrative costs increased to $8.2 million due to personnel changes. The company posted a net loss of $32.6 million for Q2, with a net loss per share of $1.15, up from a $0.4 million loss in Q2 2021.
AnaptysBio, a clinical-stage biotechnology firm, is set to participate in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, at 3:30 p.m. ET. CEO Dan Faga and CMO Paul Lizzul will represent the company. The presentation will be available via live audio webcast on AnaptysBio's investor website, with a replay accessible for 90 days post-event. AnaptysBio specializes in immunology therapeutics, with a focus on developing innovative treatments for inflammatory diseases, leveraging its proprietary antibody discovery platform.
AnaptysBio, a clinical-stage biotechnology company (Nasdaq: ANAB), announced that CEO Dan Faga and CMO Paul Lizzul will speak at the Jefferies Healthcare Conference on June 8, 2022, at 10:00 a.m. ET. A live audio webcast will be accessible on their investor website, with a replay available for 90 days.
The company develops first-in-class antibodies targeting inflammation and immuno-oncology. Their pipeline includes imsidolimab for dermatological conditions and rosnilimab for alopecia areata, among others, utilizing their proprietary somatic hypermutation platform for antibody discovery.
AnaptysBio reported its Q1 2022 financial results with cash reserves at approximately $596.8 million. The company anticipates key trial data releases: the GEMINI-1 Phase 3 trial for imsidolimab in generalized pustular psoriasis by Q4 2023, and top-line results from the HARP Phase 2 trial for hidradenitis suppurativa in Q3 2022. A decrease in collaboration revenue to $1.0 million was noted, down from $11.2 million in Q1 2021. R&D expenses decreased to $22.5 million, while G&A expenses surged to $10.2 million due to one-time costs. The net loss was $36.3 million, reflecting a per-share loss of $1.31.
AnaptysBio announced positive results from a Phase 1 trial of ANB032, a novel anti-BTLA agonist antibody. The trial demonstrated favorable safety and tolerability, with no serious adverse events. ANB032 showed a rapid and sustained pharmacokinetic profile, with a two-week half-life. The IND filing for a Phase 2 trial is expected in late 2022. Additionally, top-line data from the Phase 2 trial of Imsidolimab in moderate-to-severe hidradenitis suppurativa is anticipated in Q3 2022, while GPP Phase 3 trial data is expected in Q4 2023.
AnaptysBio (Nasdaq: ANAB) announced the appointment of Daniel Faga as interim CEO following the resignation of Hamza Suria. Faga, who has extensive experience in the biopharmaceutical industry, aims to advance the company's three clinical-stage antibody programs. AnaptysBio is conducting a strategic portfolio review while focusing on ongoing clinical trials for its lead candidates, including imsidolimab, rosnilimab, and ANB032. The company reported having approximately $615 million in cash as of the end of 2021, which will support its development activities.
AnaptysBio announced the results of the ACORN Phase 2 trial for imsidolimab in moderate-to-severe acne, revealing no significant improvement over placebo in primary and secondary endpoints. Consequently, the company will discontinue imsidolimab's clinical development for acne. However, imsidolimab showed safety and efficacy in previous trials for generalized pustular psoriasis (GPP), with ongoing enrollment in the GEMINI-1 Phase 3 trial. AnaptysBio maintains a solid financial position, ending 2021 with approximately $615 million in cash and an anticipated 2022 net cash burn between $90-$100 million.
On March 7, 2022, AnaptysBio reported its Q4 and FY 2021 results, highlighting a net loss of $32.5 million for Q4 and $57.8 million for the year. The company's cash and equivalents increased to $615.2 million, primarily due to a $250 million royalty monetization transaction with Sagard Healthcare Royalty Partners. Key pipeline updates include the initiation of the Phase 3 GEMINI-1 trial for imsidolimab in generalized pustular psoriasis, and anticipation of top-line results from multiple clinical trials in 2022, including imsidolimab for acne and hidradenitis suppurativa.
AnaptysBio, a clinical-stage biotechnology company (Nasdaq: ANAB), announced that CEO Hamza Suria will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, from 8:15 to 8:55 a.m. ET. This event focuses on the company’s innovative antibody product candidates addressing inflammation and immuno-oncology.
The presentation can be accessed via a live audio webcast on the J.P. Morgan website or AnaptysBio's investor section, with a replay available for 30 days post-conference.
On November 29, 2021, AnaptysBio, a clinical-stage biotechnology firm, appointed Daniel Faga to its Board of Directors. Faga brings over 20 years of experience in corporate strategy and finance within the biopharmaceutical sector. CEO Hamza Suria highlighted Faga's strategic vision as a valuable asset for the company's advancement of its therapeutic antibody programs. Faga expressed enthusiasm about AnaptysBio's potential and its robust, innovative pipeline targeting inflammation and immuno-oncology.
FAQ
What is the current stock price of Anaptysbio (ANAB)?
What is the market cap of Anaptysbio (ANAB)?
